secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001159036-24-000049
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme Q3 revenue up 34% to $290M; raises full-year guidance on strong royalty growth
--------------------------------------------------------------------------------

- Total revenue $290.1M (+34% YoY); royalty revenue $155.1M (+36% YoY).
- GAAP diluted EPS $1.05 (+72% YoY); Non-GAAP diluted EPS $1.27 (+69% YoY).
- 2024 guidance raised: revenue $970M-$1.02B, Adj. EBITDA $595M-$625M, Non-GAAP EPS $4.00-$4.20.
- argenx expanded ENHANZE deal (4 new targets) for $30M upfront; ViiV added another target.
- Cash and securities $666.3M, up from $336M at Dec 2023, driven by operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903624000049/0001159036-24-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903624000049/halo-20241031.htm
  HTML page:      https://secwatch.observer/filing/0001159036-24-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer